Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 4, 2000, Pages 391-400

  Mazzu, Arthur L ^a,b   Lasseter, Kenneth C ^a,b   Shamblen, E Cooper ^a,b   Agarwal, Vipin ^a,b   Lettieri, John ^a,b   Sundaresen, Pavur ^a,b  

^a Bayer Corporation Pharmaceutical Division   (United Kingdom)

^b Clinical Pharmacology Associates Miami   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450 3A4; ITRACONAZOLE; PRAVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIVER METABOLISM; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTICHOLESTEREMIC AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITRACONAZOLE; MALE; PRAVASTATIN; PYRIDINES; PYRROLES; REFERENCE VALUES; TIME FACTORS;

EID: 0033745108     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.110537     Document Type: Article

References (28)

1. Current and future treatment of hyperlipidemia: The role of statins
2. Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: A multinational, randomised, double-blind study-Ceriva statin Study Group
3. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia
4. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: The pivotal placebo controlled clinical trial
5. Clinical efficacy and safety of cerivastatin: Summary of pivotal phase IIb/III studies
6. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: The pivotal placebo-controlled clinical trial-Cerivastatin Study Group
7. The 0.4 mg dose of cerivastatin: Comparative safety and efficacy of cerivastatin 0.3 mg versus fluvastastin 40 mg
8. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver
9. 'Fire and forget?' - Pharmacological considerations in coronary care
10. Grapefruit juicesimvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors
11. Atorvastatin: A hydroxymethylglutarylcoenzyme A reductase inhibitor
12. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
13. Metabolism of cerivastatin by human liver microsomes in vitro: Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved
14. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
15. Preclinical and clinical pharmacology of cerivastatin
16. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
17. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
18. Effect of itraconazole on the pharmacokinetics of atorvastatin
19. Minor alterations in cerivastatin pharmacokinetics by erythromycin and itraconazole
20. Effect of itraconazole on cerivastatin pharmacokinetics
21. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease
22. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin
23. The interaction of diltiazem with lovastatin and pravastatin
24. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid
25. Erythromycin coadministration increases plasma atorvastatin concentrations
26. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole
27. Rhabdomyolysis associated with lovastatin and erythromycin use
28. Biopharmaceutical profile of cerivastatin: A novel HMG-CoA reductase inhibitor